Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 5, 2007

Stemagen Acquires Rights to Uniparental Embryonic Stem Cell from UPenn

  • Stemagen acquired the exclusive rights to a patent for uniparental embryonic stem cells from the University of Pennsylvania. Because these stem cells are created without fertilization, they may represent an acceptable alternative for those who oppose the traditional method that requires the use of embryos that are potentially capable of reproduction, the company reports.

    “Because Stemagen has been successful in developing human uniparental embryonic stem cell lines, we believe we are uniquely positioned to capitalize on this patent,” said Stemagen CEO Samuel H. Wood, M.D., Ph.D.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »